RxDoctor Payments Data

Keith Brightbill, MD

Urology · West Columbia, SCNPI 1104049980

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,288 of the $12,245 with a category attached, or 84.0%. It is spread thinly across 51 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,653 and has fallen 51.2% since, to $1,295 in 2025.

$12,245in general payments, 2019–2025

Across 550 payments — averaging $22.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Coloplast$1K
  • Teleflex LLC$1K
  • AbbVie$953
  • Astellas Pharma US Inc$779
  • Johnson & Johnson$624
  • plus $5K from 45 others

What the payments were for

  • Travel & lodging$1,79715%
  • Food & beverage$10,28884%
  • Education$1611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,245 in reported general payments places this provider in the 85th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$1,043,554
Medicare patients
1,652
Services billed
18,869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide21$362,884
MyrbetriqMirabegron74$57,007
GemtesaVibegron22$17,997
Mirabegron ErMirabegron23$11,627
Methenamine Hippurate107$8,092
Tamsulosin Hcl400$6,664
Oxybutynin Chloride ErOxybutynin Chloride131$3,924
Tolterodine Tartrate ErTolterodine Tartrate34$3,615
Finasteride216$3,248
Potassium Citrate ErPotassium Citrate38$2,744
Silodosin20$2,529
Solifenacin Succinate26$2,339
Desmopressin Acetate33$2,205
Testosterone Cypionate15$773
Dutasteride13$500

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$624$362,88421 claims
Astellas Pharma US IncMyrbetriq$779$57,00774 claims
Sumitomo Pharma America, Inc.Gemtesa$176$17,99722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 196 urology providers in South Carolina.

Other urology in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →